Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

Overview NewsEvents & PresentationsStock Info Stock QuoteAnalyst Coverage Financials Quarterly ReportsSEC Filings Governance Governance DocumentsCommittee CompositionConfidential & Anonymous Financial Concern HotlineCode of Business Conduct & Ethics HotlineData Privacy Requests Resources Investor FAQsInformation Request FormInvestor Email AlertsInvestor Contacts View all news 05/05/2026 Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12 at 4:20 p.m. PT / 7:20 p.m. ET in Las Vegas, Nevada. A live webcast of the fireside chat will be available at https://investors.vir.bio and will be archived for 30 days. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website. Vir Biotechnology retains exclusive rights to the PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company. Source: Vir Biotechnology Multimedia Files: View all news